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Introduction
Antithrombin is a natural anticoagulant that plays a pivotal role in coagulation homeostasis by inhibiting thrombin and factor Xa and, to a lesser extent, factors IXa, XIa and XIIa, tissue plasminogen activator, urokinase, trypsin, plasmin and kallikrein [1] [2] [3] [4] . Normal plasma activity levels are in the range of 80-120%, where 100% of antithrombin corresponds to 1 unit of antithrombin in 1 mL of reference plasma. With congenital antithrombin deficiency, functional antithrombin levels are often reduced to 40-60% of normal, leading to an increased risk of both first and recurrent venous thromboembolism (VTE) [5] [6] [7] . Although there are some other reasons, except from inheritance, for why antithrombin can be lower than normal, such as slightly lower levels in women taking birth control pills and elderly men, these levels are usually not below 70% and are not considered clinically meaningful [8] . It is in this respect surprising that one cohort study showed that patients with mild, but not necessarily inherited, antithrombin deficiency (antithrombin activity, 70-80%) had a 2.4-fold (95% confidence interval [CI], 1.5-3.8) increased risk of recurrent VTE as compared with patients with normal antithrombin levels (> 80%). For patients with antithrombin activity below 70%, this risk was 3.5-fold (95% CI, 2.2-5.6) increased [9] . Based on these findings, and on the finding that these levels were not associated with an increased bleeding risk (either on or off anticoagulant treatment), the authors suggested that patients with VTE should be extensively screened for mild antithrombin deficiency and that the duration of antithrombotic therapy for VTE in patients with antithrombin activity below 80% (nearly 10% of their population) should be indefinite. However, these results have not been confirmed by other studies, and the recommendation is not implemented in ACCP guidelines.
We therefore aimed to externally validate whether mild antithrombin deficiency is a risk factor for recurrent VTE without increasing the risk of major bleeding by determining this risk in a large group of patients (n = 2357) who had a first venous thrombotic event and who were followed for a median of 7.4 years.
Methods

Patients
This study is comprised of patients with a first VTE who participated as cases in the MEGA study, a population-based case-control study (n = 4956). Details have been given previously [10] . In brief, between March 1999 and August 2004, consecutive patients with an objectively diagnosed first deep vein thrombosis of the leg or pulmonary embolism were included. Patients were aged 18-70 years and were enrolled from six anticoagulation clinics in the Netherlands. All patients filled in an extensive questionnaire on putative risk factors for VTE and blood was sampled from patients included until June 2002 for logistic reasons. Of 4956 eligible patients, 4731 gave informed consent for follow-up (MEGA follow-up study), 2388 of whom had donated bloods. These patients were followed from their first episode of acute VTE.
Between 2007 and 2009 the vital status of all MEGA follow-up participants was acquired from the central Dutch population register, as has been described previously [11] . For the patients who died, the cause of death (encoded according to International Classification of Diseases ICD-10-CM) was obtained from the national register of death certificates at the Central Bureau of Statistics. This study was approved by the Medial Ethics Committee of the Leiden University Medical Center.
Recurrent venous thromboembolism
Questionnaires concerning recurrent VTE were sent by mail between June 2008 and July 2009. Questions were asked by telephone interview when questionnaires were not returned. During the same period, information about recurrences was retrieved from the anticoagulation clinics where patients were initially included for their first event and, if they had moved house, also from the clinic nearest to their new address. Deaths due to recurrent VTE were counted as fatal recurrent events. Discharge letters were requested from the clinician who had diagnosed the recurrence. A decision rule regarding certainty of the diagnosis was made according to the information collected per patient. Possible recurrences were classified into certain recurrences and uncertain recurrences. Details of this decision rule have been described previously [12] . In short, reported recurrences were classified as certain when (i) a discharge letter stated a diagnosis of a recurrent event based on clinical and radiological data, or (ii) both the anticoagulation clinic and the patient reported a recurrent event that was at a clearly different location from the first event or occurred more than 1 year since the first event, or (iii) a registered death from a recurrent event at least 6 months after the first event was found. For this analysis, we considered certain recurrences as outcome event only.
Major bleeding
Data from the MEGA study were linked to the Dutch Hospital Data register in 2011 by Statistics Netherlands. The Dutch Hospital Data register provides nationwide electronic coverage of data on hospital admissions since 1995 [13] . Diagnosis at discharge is determined by the treating physician and subsequently coded by trained hospital staff according to the International Classification of Diseases, ninth version, clinical modification (ICD-9-CM). A total of 2183 (93%) of MEGA follow-up participants included in this study could be individually linked to records of the Dutch Hospital Data register. In this register, we searched for hospital admissions for major bleeding in MEGA patients, according to the classification described by Schalekamp et al. [14] . Causes of death due to major hemorrhage were additionally included in the analysis.
Inclusion/exclusion criteria
In our main analysis, we did not exclude any patient to avoid selection bias. However, because the goal of our study was to assess whether mild antithrombin deficiency is a risk factor for recurrent VTE, similar to the study previously published on this issue [9] , we decided to perform sensitivity analyses in which we adopted similar exclusion criteria to those that were employed in the study from Di Minno et al. [9] . With this approach, we safeguard a deviation from the Di Minno study that could be related to selection bias. Therefore, we excluded in these sensitivity analyses patients with protein C or protein S deficiency, self-reported liver disease or pregnancy/puerperium, and users of oral contraceptives or hormonal replacement therapy. Of note, the approach of identifying protein S or protein C deficiency by a protein level only is controversial (as for this, identification of genetic protein C or S deficiency is also needed), but was not followed in the MEGA study to remain as similar as possible to the Di Minno et al. study where protein C and protein S deficiency were defined by a protein level only [9] . In a post hoc analysis we also excluded patients who reported drinking five or more glasses of alcohol per day, because alcohol intake can reduce antithrombin levels [15] .
Laboratory measurements
Approximately 3 months after discontinuation of oral anticoagulant therapy, thrombosis patients were invited for collection of a blood sample. In patients who were still on anticoagulant therapy 1 year after their event (n = 202), blood was drawn during anticoagulant therapy. Of 3120 patients eligible for blood sampling, 732 patients did not provide a blood sample. Reasons could be that patients died before the moment of blood collection (n = 180), or that patients were unable to visit the hospital or unwilling to provide a blood sample. Of the 2388 patients who provided a blood sample, antithrombin activity was not measured in 31 samples. This leaves 2357 patients to be included for analyses (Fig. 1) . Details of collection and processing of blood samples have been described previously [16] . For each patient, antithrombin activity (factor IIa based) and protein C was measured with a chromogenic assay. These measurements were performed on a STA-R coagulation analyzer following the instructions of the manufacturer (Diagnostica Stago, Asni eres, France). Total protein S levels were measured by an enzyme-linked immunosorbent assay (Diagnostica Stago). The mean intra-assay and inter-assay coefficients of variation were 1.7% and 2.6%, respectively, for antithrombin, 1.4% and 3.5% for protein C, and 5.0% and 3.5% for protein S. Patients were considered deficient for protein C or protein S when levels were below the lower limit of normal (67 U dL À1 or 33 U dL À1 when using oral anticoagulation at the blood draw) [17] .
Statistical analysis
Duration of follow-up was counted from date of first thrombotic event to end of follow-up, defined as the date of a recurrent event, and in the absence of a recurrence, the date of filling in the follow-up questionnaire. If patients did not fill in the questionnaire, they were censored at the last date we knew them to be recurrence free. This could be date of death (n = 35), date of emigration (n = 1), date of the last visit to the anticoagulation clinic (n = 46) or the last moment known to be recurrence free from information from the MEGA case-control study (n = 273). The analyses were limited to certain recurrent events only (n = 361), and patients with uncertain recurrent events were censored at that time. Cut-off values were employed using the definition of Di Minno et al., with antithrombin levels < 70%, between 70 and 80% and > 80% (reference category). Because only nine (0.4%) patients had an antithrombin activity < 70% in our study (of whom one used anticoagulation at time of blood draw) and 27 (1%) had an antithrombin activity between 70 and 80%, we decided to show differences between groups according to percentile cut-off points of antithrombin as well. These cut-off points were < 5th percentile of the antithrombin level (i.e. < 87%), between the 5th and 10th percentiles of antithrombin levels (i.e. between 87 and 92%) and ≥ 10th percentile (i.e. ≥ 92%) in patients with VTE included in the MEGA-follow up study. We compared positive family history of VTE [18] in those with lower levels (i.e. < 87% or < 5th percentile of antithrombin) and those with higher levels of antithrombin in order to study if a signal of mild antithrombin deficiency could be related to a positive family history. Incidence rates of recurrent VTE were estimated as the number of events over the accumulated follow-up time. Cox-proportional hazards models were used to evaluate risks between groups and were adjusted for age and sex in the overall analyses. By means of log (Àlog) survival curves and by adding an interaction term between time and categories of antithrombin in a Cox model, the assumption of proportional hazards over time was tested. Hazard ratios for recurrence were estimated for decreasing levels of antithrombin activity. KaplanMeier curves were constructed to estimate the cumulative incidence of recurrent VTE over the years, for various antithrombin activity levels. The cumulative incidence competing risk (CICR) method was used to account for death as a competing risk [19] . All analyses were performed with SPSS version 23.0 (SPSS Inc, Chicago, IL, USA).
Results
Baseline Data
A total of 2357 patients were included in the main analysis ( Fig. 1) . Table 1 shows the general characteristics of the study population. Of enrolled patients, 1074 (46%) were men and the mean age at time of first VTE was 48 years (range 18-70 years). After their first event, 2099 (89%) patients received vitamin K antagonist (VKA) treatment for ˂ 1 year and 258 (11%) for more than 1 year. Protein C or protein S deficiency was present in 88 patients, self-reported liver disease in 15 patients, pregnancy/puerperium in 94 women, and use of oral contraceptives or hormonal replacement therapy in 735 women. Patients who had antithrombin activity below the 10th percentile were more often men and were slightly older than patients who had antithrombin activity that was ≥ 10th percentile. They also more often were high consumers of alcohol and more often had a first deep vein thrombosis and unprovoked first event.
Recurrent venous thromboembolism
During follow-up, recurrent VTE occurred in 361 patients for an incidence rate of 2.5 (95% CI, 2.3-2.8) per 100 person-years. Table 2 shows the risk of recurrent VTE for strata of percentile cut-off antithrombin activity. The incidence rates (per 100 patient-years) were 2.4 (95% CI, 2.2-2.7), 2.8 (95% CI, 1.7-4.5) and 3.9 (95% CI, 2.5-5.9) for antithrombin levels in the ≥ 10th, 5th-10th and < 5th Continuous variables denoted as mean (range), categorical variables as number (%). Some data were missing for some variables. *As concomitance of provoked risk factors occurred frequently, patients could be counted twice or more.
percentile cut-off categories, respectively. We observed an increased risk of recurrent VTE in the lowest antithrombin activity category (< 5th percentile; < 87%) as compared with antithrombin activity that was ≥ 10th percentile (i.e. ≥ 92%), with an adjusted hazard ratio of 1.5 (95% CI, 1.0-2.3). When we stratified our analyses to the antithrombin cut-off criteria employed by Di Minno et al. [9] , the adjusted hazard ratio of venous recurrence was 3.7 (95% CI, 1.4-9.9) in patients who had antithrombin activity < 70% as compared with patients who had antithrombin activity ≥ 80%. When follow-up started at time of ending anticoagulant treatment, this adjusted hazard ratio of recurrent VTE was 3.8 (95% CI, 1.4-10.3). Exclusion of patients who drank five or more glasses of alcohol per day did not change the main outcome, with an age and sex-adjusted hazard ratio of 1.5 (95% CI, 1-2.3) for recurrent VTE for patients who had < 87% antithrombin levels as compared with those who had antithrombin levels ≥ 92%. Sensitivity analyses in which we either started followup after discontinuation of VKA treatment, or where we confined our data to the selection criteria of Di Minno et al. [9] , did not materially affect this main result (i.e. an increased risk of recurrent VTE when patients with antithrombin activity < 87% were compared with patients who had antithrombin activity ≥ 92%). Patients who did not have malignancy at baseline were also at increased risk of recurrent VTE when their antithrombin activity was < 87% in comparison with patients who had antithrombin activity ≥ 92% (Table S1 ). Figure 2 shows that, when compared with antithrombin activity ≥ 92%, the increased risk of recurrent VTE started around an antithrombin activity at or below 87%, and was highest in patients who had antithrombin activity below 70% (adjusted hazard ratio of 3.7; 95% CI, 1.4-9.9). Patients with antithrombin levels < 87% more often had a positive family history of VTE (n = 35; 39%) than those who had an antithrombin level ≥ 87% (n = 604; 31%); odds ratio 1.5 (95% CI, 0.95-2.3). 
Recurrence rates in subgroups
When only patients with unprovoked first VTE (n = 807) were analyzed, recurrence occurred in 15 patients with antithrombin activity < 87% (incidence rate, 5.9 per 100 person-years; 95% CI, 3.3-9.7), and in 176 patients with antithrombin activity ≥ 87% (incidence rate, 3.9 per 100 person-years; 95% CI, 3.3-4.5) ( Table 3 ; Kaplan-Meiers provided in Figures S1 and S2 ). As expected [20] , absolute recurrence rates were lower in all subgroups of patients with provoked first VTE than in those with unprovoked first VTE. Yet, the relative risk of recurrent VTE in patients with antithrombin in the lowest category (< 87%, as compared with antithrombin activity ≥ 87%) was similar for patients with provoked (hazard ratio, 1.4; 95% CI, 0.7-2.8) and unprovoked first VTE (hazard ratio, 1.5; 95% CI, 0.9-2.6).
When the analysis was restricted to men or women only, a similar pattern was observed; that is, a higher absolute risk of recurrent VTE in men than in women [21] , and an increased relative risk of recurrent VTE in patients with antithrombin in the lowest category (< 87%, as compared with patients who had antithrombin activity levels that were ≥ 87%) in both men (hazard ratio, 1.5; 95% CI, 0.9-2.5) and women (hazard ratio, 1.4; 95% CI, 0.7-3.0).
Cumulative incidence of recurrent venous thromboembolism
The cumulative incidence of recurrent VTE at 2, 4, 6 and 8 years was 6%, 10%, 13% and 17%, respectively, in the group of patients with antithrombin activity ≥ 92%, and approximately equal to the cumulative incidence of patients with an antithrombin activity between 87 and 92% (Fig. 3) . In contrast, the cumulative incidence was higher at these time-points in patients who had antithrombin activity < 87%, for whom the cumulative incidence was 10% at 2 years, 15% at 4 years, 19% at 6 years and 25% at 8 years.
Bleeding complications
Of 2357 patients, 2183 (93%) could be linked to the Dutch Hospital Data register. During follow-up, 76 major bleeding episodes occurred (Table 4) , representing an incidence rate of 0.39 (95% CI, 0.31-0.49) per 100 patients per year. As expected, the incidence rate of major bleeding was higher when patients were on VKA treatment (1.13 per 100 patients per year) than off VKA treatment (0.31 per 100 patients per year). With stratification for antithrombin activity, major bleeding occurred in 71 patients with antithrombin activity ≥ 92%, in two of those with antithrombin activity 87-92% and in three of those with antithrombin activity < 87%, with no apparent difference in the incidence rate of bleeding between these three groups. CI denotes confidence interval; py, person years. *Start follow-up after discontinuation of VKA treatment. †Restricted to exclusion criteria as defined in the Di Minno study. ‡Restricted to exclusion criteria as defined in the Di Minno study, start follow-up after discontinuation of VKA treatment.
Discussion
This study confirms that mild antithrombin deficiency is associated with a 1.6-3.7-fold increased risk of recurrent VTE, depending on the cut-off value that is used (i.e. either < 87% or < 70%). Mild antithrombin deficiency was able to predict recurrent VTE over a long period of time and appeared to be more present in patients with a positive family history for VTE (odds ratio, 1.5; 95% CI, 0.95-2.3). The incidence rate of major bleeding appeared to be similar in those with mild antithrombin deficiency and patients who had normal antithrombin activity. Our results are in line with a previous study, which showed that the association between mild antithrombin deficiency and recurrent VTE is present when antithrombin activity levels are below 80%, and in which the bleeding rate appeared not to depend on the antithrombin activity level [9] . Our results are also in line with a metaanalysis that showed that mild antithrombin deficiency is a risk factor for first VTE in non-family-based studies [22] . So, what are the clinical implications from our study?
Although it is tempting to speculate that patients with VTE should be extensively screened for mild antithrombin deficiency and that the duration of antithrombotic therapy for VTE in patients with mild antithrombin deficiency should be prolonged [9] , there are considerations that preclude such a conclusion. First, from our findings one can estimate the population attributable risk (PAR) of antithrombin deficiency for recurrent VTE. Depending on the cut-off level that is used, this PAR is 2.4% when antithrombin activity is < 87%, and 0.7% when antithrombin activity is < 70%. Because the PAR is a function of the proportion of a disease in a particular population that can be attributed to the risk factor under study, or, in other words, by which proportion the frequency of recurrent VTE would decrease if mild antithrombin deficiency were eliminated, we would conclude that the PAR for antithrombin deficiency and recurrent VTE is too low to support routine testing for antithrombin levels. Second, even if one would find a mild antithrombin deficiency in a patient with VTE, one should consider whether effective anticoagulant treatment to prevent recurrence outweighs the bleeding risk associated with continued anticoagulant treatment. This does not seem to be the case for mild antithrombin deficiency. For example, the risk of recurrent VTE is 8.1% in the first 2 years after anticoagulation is withdrawn in patients with an antithrombin activity below 87% ( Table 2) .
The question is whether anticoagulant treatment should be continued if this risk then drops to 0.5% at the cost of an approximately 2.2% risk of a major bleeding event in 2 years (Table 4) . In this example, the additional mortality risk for bleeding would not outweigh the mortality benefit of reduced thrombosis: 8.1% risk 9 3.6% casefatality rate of recurrent VTE [23] = 0.29% fatal events without continuation of anticoagulant treatment vs. 2.2% risk 9 11.0% case-fatality rate of major bleeding [23] = 0.24% fatal bleeding events + 0.5% risk 9 3.6% case-fatality rate of recurrent VTE = 0.26% fatal events with continued anticoagulant treatment. Third, VTE is a multi-causal disease and prediction of recurrence based on one factor is unlikely to be sufficient to guide treatment duration [24, 25] . Nevertheless, as antithrombin is a protein that can be accurately measured both during and after anticoagulant treatment with vitamin-K antagonists, Antithrombin ≥ 92% Antithrombin 87-92% Antithrombin < 87% Fig. 3 . Analysis of survival free from recurrent venous thromboembolism. low antithrombin levels could be useful as an additional marker in a prediction model for recurrent VTE. A strength of our research lies in the large study size, in the study design (three types of sensitivity analyses in which we adopted similar exclusion criteria to those employed in the study from Di Minno et al. [9] ) and long follow-up time. In addition, our study showed results comparable to the study of Di Minno et al. [9] . For these reasons, we consider a type I error unlikely, as an alternative explanation for our findings. Another strength is its generalizability, as the MEGA follow-up study consists of consecutive patients with VTE who were enrolled through anticoagulation clinics without any exclusion criteria. This contrasts with the design from Di Minno et al., who included their patients from a tertiary care setting with many exclusion criteria [9] . Combined with the study of Di Minno et al., we are therefore confident that mild antithrombin deficiency is associated with an increased risk of recurrent VTE.
Limitations of our study should also be mentioned. First, antithrombin levels were only measured once over follow-up, which could have led to misclassification. However, in the study by Di Minno et al. [9] antithrombin activity levels were measured twice and antithrombin activity appeared to be fairly constant. Nevertheless, patients with low antithrombin levels due to alcohol intake can have fluctuating antithrombin levels [15] . However, in a post hoc analysis, our main result seemed not to be influenced by alcohol intake because mild antithrombin deficiency was still associated with a 1.5 (95% CI, 1-2.3) increased risk of recurrent VTE after we excluded patients who reported drinking five or more glasses of alcohol per day. Second, antithrombin activity levels were not measured in all patients, mainly because of logistic reasons. However, some may have been missing in those patients who were sickest. Although this does not compromise the internal validity of our results, it may imply that our results are generalizable only to those patients well enough to provide a blood sample. Third, because we used a strict definition of recurrent VTE and included only certain recurrences in our study, incidence rates and cumulative incidences may have been slightly underestimated. Fourth, subgroup analyses were precluded by small numbers, which sometimes resulted in wide confidence intervals. However, considering the point estimates, there was an association between mild antithrombin deficiency and risk of recurrence, both in patients with unprovoked and in patients with provoked first events, and in men and women. Fifth, the lower limit of antithrombin < 60% (often used in the diagnosis of heritable antithrombin deficiency) was not used in this study, where only three patients had antithrombin levels < 60%.
In addition, it would be of interest to perform genotyping in the patients with lower antithrombin levels to confirm the genetic background of this abnormality, but this was also beyond the scope of the present study, where we wanted to externally validate whether mild antithrombin deficiency (as defined by Di Minno et al. [9] ) is a risk factor for recurrent VTE. In conclusion, this study demonstrates that mild antithrombin deficiency is a risk factor for recurrent VTE. Fig. S1 . Recurrent venous thrombosis free survival analysis in patients with unprovoked first venous thromboembolism. Fig. S2 . Recurrent venous thrombosis free survival analysis in patients with provoked first venous thromboembolism. Table S1 . Risk of recurrent venous thrombosis for strata of antithrombin percentage levels.
